PDF(Pubmed)
Abstract：
Objectives: Studies on the prognosis and risk stratification of patients with acquired immune deficiency syndrome (AIDS) - related Burkitt lymphoma (AR-BL) are rare. We aim to construct a novel model to improve the risk assessment of these patients. Methods: We retrospectively analyzed the clinical data of 34 patients over the past 10 years and the factors associated with progression-free survival (PFS) and overall survival (OS) were evaluated in univariate and multivariate Cox models. Then, the novel model consisting of screened factors was compared with the existing models. Results: With a 37-month median follow-up, the overall 2-year PFS and OS rates were 40.50% and 36.18%, respectively. The OS of patients who received chemotherapy was better compared with those without chemotherapy (P = .0012). Treatment with an etoposide, prednisone, oncovin, cyclophosphamide, and hydroxydaunorubicin-based regimen was associated with longer OS and PFS compared with a cyclophosphamide, doxorubicin, vincristine, and prednisone-based regimen (OS, P = .0002; PFS, P = .0158). Chemotherapy (hazard ratio [HR] = 0.075; 95% confidence interval [CI], 0.009-0.614) and Eastern Cooperative Oncology Group Performance Status (ECOG PS) 2 to 4 (HR = 4.738; 95% CI, 1.178-19.061) were independent prognostic factors of OS in multivariate analysis and we established a novel prognostic risk stratification model named GZ8H model with chemotherapy and ECOG PS. Conclusion: GZ8H showed better stratification ability than the international prognostic index (IPI) or Burkitt lymphoma IPI (BL-IPI). Furthermore, the C-index of the nomogram used to predict OS was 0.884 in the entire cohort and the calibration curve showed excellent agreement between the predicted and actual results of OS. No human immunodeficiency virus-related factors were found to be associated with OS and PFS of AR-BL patients in our study. Overall, the clinical characteristics and outcomes in AR-BL were shown and prognostic factors for OS and PFS were identified in this study.
摘要：
目的：获得性免疫缺陷综合征（AIDS）相关性伯基特淋巴瘤（AR-BL）患者的预后和危险分层的研究很少。我们旨在构建一种新的模型来改善这些患者的风险评估。方法：我们回顾性分析了34例患者过去10年的临床资料，并在单变量和多变量Cox模型中评估了与无进展生存期（PFS）和总生存期（OS）相关的因素。然后，将由筛选因子组成的新模型与现有模型进行了比较。结果：经过37个月的中位随访，总体2年PFS和OS率分别为40.50%和36.18%，分别。接受化疗的患者OS优于未接受化疗的患者（P=.0012）。用依托泊苷治疗，泼尼松,oncovin,环磷酰胺,与环磷酰胺相比，基于羟基柔红霉素的方案与更长的OS和PFS相关，阿霉素,长春新碱,和基于泼尼松的方案(OS，P=.0002；PFS，P=.0158）。化疗（危险比[HR]=0.075；95%置信区间[CI]，0.009-0.614）和东部肿瘤协作组绩效状态（ECOGPS）2至4（HR=4.738；95％CI，1.178-19.061）是多变量分析中OS的独立预后因素，我们建立了一种新的预后风险分层模型，称为GZ8H模型和ECOGPS。结论:GZ8H的分层能力优于国际预后指数(IPI)或伯基特淋巴瘤IPI(BL-IPI)。此外，在整个队列中,用于预测OS的列线图的C指数为0.884,校准曲线显示OS的预测结果与实际结果非常吻合.在我们的研究中，没有发现人类免疫缺陷病毒相关因素与AR-BL患者的OS和PFS相关。总的来说,本研究显示了AR-BL的临床特征和结局,并确定了OS和PFS的预后因素.
